Methotrexate was used as graft-versus-host disease prophylaxis in >90% of patients of the studies that assessed MTHFR except in the study by Pihusch et al. [44], which also showed a very low SOS incidence (n = 3/89, 3.4%). Here, MTHFR is linked to graft versus host disease.